{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:23:34Z","timestamp":1791869014210,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ijrobp.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:39:07Z","timestamp":1744425547000},"page":"374-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-2794","authenticated-orcid":false,"given":"Kaili","family":"Ranta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej P.","family":"Wojcieszynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang G.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Jarrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Huenerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kruser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Floberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.04.002_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semradonc.2008.04.007","article-title":"Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer","volume":"18","author":"Ritter","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0002","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0003","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0005","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0006","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of hypofractionated vs conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: The NRG-GU003 phase 3 randomized clinical trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0007","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/cncr.25824","article-title":"Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence","volume":"117","author":"Kruser","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0008","series-title":"Protocol: A randomized phase III trial of hypofractionated postprostatectomy radiation therapy (HYPORT) versus conventional post-prostatectomy radiation therapy (COPORT)","author":"Buyyounouski","year":"2019"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.eururo.2014.07.036","article-title":"Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer","volume":"66","author":"Buyyounouski","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/153303460300200511","article-title":"3D-ultrasound guided radiation therapy in the post-prostatectomy setting","volume":"2","author":"Chinnaiyan","year":"2003","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0012","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0013","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00468-3","article-title":"Late GI and GU complications in the treatment of prostate cancer","volume":"37","author":"Schultheiss","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.291.11.1325","article-title":"Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy","volume":"291","author":"Stephenson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0016","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","article-title":"Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: A single-institution analysis of 1176 patients","volume":"66","author":"Cozzarini","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0017","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2015.11.025","article-title":"Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer","volume":"94","author":"Lewis","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0018","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2018.02.002","article-title":"Postoperative radiation therapy for prostate cancer: Comparison of conventional versus hypofractionated radiation regimens","volume":"101","author":"Tandberg","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0019","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2006.11.024","article-title":"Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy","volume":"67","author":"Neuhof","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2008.07.027","article-title":"Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy","volume":"89","author":"De Meerleer","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2003.12.043","article-title":"Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer","volume":"21","author":"Katz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urolonc.2003.12.001","article-title":"Salvage radiation for a rising PSA following radical prostatectomy","volume":"22","author":"Maier","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0023","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.urology.2004.06.020","article-title":"Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival","volume":"64","author":"Pacholke","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0024","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2023.04.032","article-title":"Salvage radiation therapy after radical prostatectomy: Analysis of toxicity by dose-fractionation in the RADICALS-RT trial","volume":"117","author":"Petersen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The alpha\/beta ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0026","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2011.10.069","article-title":"The timing of salvage radiotherapy after radical prostatectomy: A systematic review","volume":"84","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0027","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: Analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0028","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0029","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clon.2004.07.006","article-title":"Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy","volume":"16","author":"Lee","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2014.08.061","article-title":"Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both","volume":"67","author":"Jarosek","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bju.15769","article-title":"Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study","volume":"130","author":"Braide","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0033","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.juro.2007.03.126","article-title":"Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE","volume":"178","author":"Elliott","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0034","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/s12885-023-11278-3","article-title":"Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)","volume":"23","author":"Marciscano","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2022.08.041","article-title":"Quality-of-life outcomes and toxicity profile among patients with localized prostate cancer after radical prostatectomy treated with stereotactic body radiation: The SCIMITAR multicenter phase 2 trial","volume":"115","author":"Ma","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0036","article-title":"Toxicity profile and patient-reported outcomes following salvage stereotactic ablative radiation therapy to the prostate Bed: The POPART multicentric prospective study","volume":"44","author":"Ferrario","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.04.002_bib0037","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: The SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:21:13Z","timestamp":1757071273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625003621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0360301625003621"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}